Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
China SXT Pharmaceuticals ( (SXTC) ) just unveiled an update.
China SXT Pharmaceuticals, Inc. recently executed a securities purchase agreement on May 16, 2025, which involved selling 10 million ordinary shares and issuing warrants for up to 100 million shares. Between May 30 and June 2, 2025, investors exercised these warrants under a cashless provision, resulting in the issuance of 90 million underlying shares. As of June 10, 2025, the company’s total issued and outstanding shares amounted to 116,027,758. This transaction, facilitated through a prospectus supplement and a shelf registration statement, reflects the company’s strategic financial maneuvers to enhance its capital structure and potentially strengthen its market position.
More about China SXT Pharmaceuticals
China SXT Pharmaceuticals, Inc. operates in the pharmaceutical industry, primarily focusing on the development and sale of traditional Chinese medicine products. The company is based in Taizhou, Jiangsu, China, and is involved in the production of various medicinal products aimed at addressing a range of health conditions.
Average Trading Volume: 4,366,896
Technical Sentiment Signal: Sell
Current Market Cap: $47.63M
Find detailed analytics on SXTC stock on TipRanks’ Stock Analysis page.